Stock CRBP CORBUS PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
50.1 USD -5.28% Intraday chart for Corbus Pharmaceuticals Holdings, Inc. +13.53% +729.47%
Jun. 12 Transcript : Corbus Pharmaceuticals Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:40 PM
Jun. 11 RBC Raises Price Target on Corbus Pharmaceuticals Holdings to $82 From $77, Maintains Outperform, Speculative Risk MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RBC Raises Price Target on Corbus Pharmaceuticals Holdings to $82 From $77, Maintains Outperform, Speculative Risk
MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $80 From $60, Maintains Outperform Rating
MT
RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target
MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating
MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating
MT
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold
MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $51 From $20, Maintains Outperform Rating
MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $20 From $22, Maintains Outperform Rating
MT
Oppenheimer Upgrades Corbus Pharmaceuticals to Outperform From Perform, $22 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRBP Stock
  4. News Corbus Pharmaceuticals Holdings, Inc.
  5. Analyst Reco.